Including genetic criteria, especially the clonal architecture, in leukemia classification will allow pathologists to identify the type of cancer being treated at a molecular level. This will allow clinicians to select certain drugs and avoid others based on disease type and make a more accurate prognosis for the course of the disease.
New Clinic Tackles Mutations That Increase Risk of Blood Cancers and Heart Disease
Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
Survival Trends in Infant Allogeneic Cell Transplant Recipients: Limited Progress
An analysis of outcomes for infant allogeneic hematopoietic transplant recipients finds mixed results, with some signs of progress but no recent survival gains in patients with malignant diagnoses.
Azacitidine Shows Potential in Treating AML and MDS Relapse Following Stem Cell Transplantation
Azacitidine could help patients with acute myelogenous leukemia or myelodysplastic syndrome who relapse after transplant achieve remission.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Mutation Clonal Burden and Transplantation Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Although studies have established the prognostic significance of specific genetic mutations in AML and MDS, the role of mutations as prognostic factors of outcomes after HCT is still unclear.
The Next Step in Immunotherapy for Myeloid Hematologic Malignancies
A multicenter team studied the safety of immunotherapy atezolizumab in patients with myelodysplastic syndrome who had either failed or never received conventional HMA therapy.